AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (F...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 2,069
- Institution
- AstraZeneca (Singapore)
External Links
Identifiers
- ORCID
- 0000-0001-6566-8915
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.